KEY TAKEAWAYS
- The study aimed to evaluate the efficacy and safety of lenvatinib + pembrolizumab in patients with advanced recurrent EC.
- Results showed that lenvatinib + pembrolizumab provided clinical benefits but caused significant toxicity in advanced recurrent EC.
Multiple trials have shown that lenvatinib combined with pembrolizumab offers clinical benefits for advanced or recurrent endometrial cancer (EC), regardless of mismatch repair (MMR) status or histologic subtype. However, most of these studies had small sample sizes.
Guangwei Yan and the team aimed to evaluate the efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent EC.
The study reviewed clinical trials from the Cochrane Library, PubMed, Web of Science, and Embase databases to assess the efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent EC.
Researchers analyzed outcomes including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and the incidence of adverse events (AEs). Subgroup analysis was conducted based on MMR status, including deficient (dMMR) and proficient (pMMR) cases.
The results showed that 4 trials involving 582 patients were included in the analysis. The pooled ORR was 32.7% [95% CI: 28.9-36.5]. Subgroup analysis indicated an ORR of 48.1% (95% CI: 26.1-70.2) for the dMMR group and 33.1% (95% CI: 25.7-40.6) for the pMMR group. The pooled DCR was 74.9% (95% CI: 71.3-78.4%), with subgroup analysis showing a DCR of 81.0% (95% CI: 64.5-97.6) for the dMMR group and 76.3% (95% CI: 66.3-86.3) for the pMMR group.
All studies reported follow-up data, with a median PFS ranging from 5.3 months to 258 days and OS ranging from 17.2 months to not reached. Regarding safety, the overall pooled proportions of any-grade AEs and AEs of grade 3 or higher were 95.8% (95% CI: 89.5-100.0) and 80.2% (95% CI: 59.9-100.0), respectively.
The study concluded that lenvatinib plus pembrolizumab provided significant clinical benefits but also considerable toxicity for patients with advanced and recurrent EC. Further research is needed to evaluate long-term outcomes.
This study was supported by Higher Education Key Scientific Research Plan of Henan Province.
Source: https://pubmed.ncbi.nlm.nih.gov/39185408/
Yan G, Du Y, Zhang H, et al. (2024). “Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis.” Front Immunol. 2024;15:1404669. Published 2024 Aug 9. doi:10.3389/fimmu.2024.1404669
